Revvity Inc (NASDAQ: RVTY) saw its shares gain in premarket trading Thursday, rising 2.7% to $88.8 following the release of first-quarter results that outpaced Wall Street forecasts.
The company reported adjusted earnings of $1.06 per share for the quarter, above the average analyst estimate of $1.02 per share. The quarterly outperformance came alongside a more conservative outlook for fiscal 2026: Revvity trimmed its adjusted profit guidance to a range of $5.20 to $5.30 per share, down from an earlier forecast of $5.35 to $5.45 per share. Analysts had been modeling annual adjusted profit of $5.39 per share for 2026.
In the same announcement, Revvity said it has decided to sell its immunodiagnostics business in China. Management indicated that the China immunodiagnostics unit represented approximately 6% of total revenue in fiscal 2025.
Market positioning ahead of Thursday's session left Revvity shares down 10.6% year-to-date prior to the update. The premarket uptick followed the quarterly beat but also came in the context of a reduced full-year profit range.
For investors and market participants, the reporting package combined a near-term earnings beat with a recalibration of expectations for the coming fiscal year and a strategic move to divest a China-based diagnostic operation that made up a modest share of revenue in the most recent fiscal year.
Details provided by the company establish the key numeric outcomes: adjusted Q1 EPS of $1.06 versus a $1.02 consensus, a lowered 2026 adjusted EPS range of $5.20 to $5.30 versus a prior range of $5.35 to $5.45, and the China immunodiagnostics business representing about 6% of fiscal 2025 revenue. Prior to the earnings release and guidance revision, the stock had declined 10.6% year-to-date.
Market reaction: Shares rose 2.7% in premarket trading to $88.8 after the report.
Outlook: Revvity narrowed and lowered its fiscal 2026 adjusted profit guidance to $5.20 to $5.30 per share; analysts had expected $5.39.
Corporate action: The company announced plans to sell its China immunodiagnostics business, which accounted for roughly 6% of total revenue in fiscal 2025.